Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 29 |
| Active Pipeline (Recruiting Now) | 13 (9) |
| Completed vs Stopped Early | 11 / 5 (17.2%) |
| Median Closed Actual Enrollment | 47 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 4 (4 since 2018) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Alnylam Pharmaceuticals across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Alnylam Pharmaceuticals Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.